Clinical bottom line
Inhaled anti-IL-6 therapies represent a putative targeted approach to mitigate severe lung injury in COVID-19 by locally modulating the hyperinflammatory response implicated in acute respiratory distress syndrome (ARDS). Current evidence remains preliminary and largely hypothesis-generating, with no definitive clinical trial data supporting routine use. While systemic IL-6 blockade has shown mixed results in severe COVID-19, inhaled delivery may offer theoretical advantages in maximizing pulmonary bioavailability and minimizing systemic immunosuppression. Clinicians should consider inhaled anti-IL-6 agents as an experimental adjunct within clinical trials or compassionate use frameworks pending robust efficacy and safety validation.
What the evidence shows
Severe COVID-19-related lung injury is characterized by dysregulated immune activation and cytokine storm, with IL-6 identified as a key mediator driving pulmonary inflammation and fibrosis. Systemic IL-6 receptor antagonists, such as tocilizumab, have been evaluated extensively but with variable outcomes, partly due to systemic side effects and timing of administration. The concept of inhaled anti-IL-6 therapies aims to deliver targeted anti-inflammatory effects directly to the lung parenchyma, potentially improving therapeutic index.
Preclinical and early clinical data on inhaled anti-inflammatory agents support the feasibility of this approach in lung injury contexts (Lung Injury, 2005). However, specific evidence for inhaled anti-IL-6 therapies in COVID-19 remains sparse. Reviews on severe COVID-19-related ARDS highlight the urgent need for novel interventions to prevent progression to irreversible lung damage and transplantation (Lung transplantation for severe COVID-19-related ARDS, 2021–2022). These reviews emphasize the inflammatory milieu but do not yet provide conclusive data on inhaled IL-6 blockade.
The rationale for inhaled delivery is supported by the pathophysiology of COVID-19 lung injury, where localized cytokine overproduction contributes to alveolar damage and fibrosis. Targeting IL-6 locally may reduce systemic immunosuppression risks and allow higher pulmonary drug concentrations. Nonetheless, clinical trial evidence is currently lacking, and the reviewed literature underscores this as an emerging, unproven strategy warranting rigorous investigation.
Caveats and uncertainty
The primary limitation is the absence of randomized controlled trials evaluating inhaled anti-IL-6 therapies in COVID-19 or other ARDS etiologies. The safety profile, optimal dosing, timing, and patient selection criteria remain undefined. Potential risks include local immunosuppression leading to secondary infections or impaired viral clearance.
Moreover, the heterogeneity of COVID-19 lung injury phenotypes complicates therapeutic targeting. The inflammatory cascade involves multiple cytokines beyond IL-6, and monotherapy may be insufficient. Systemic IL-6 blockade trials have shown variable efficacy, suggesting that IL-6 is only one component of a complex network.
The reviewed literature on lung transplantation for COVID-19-related ARDS (2021–2022) highlights the severity of lung damage in refractory cases but does not address inhaled anti-IL-6 therapy outcomes, reflecting a gap in evidence. Thus, current understanding is largely theoretical and extrapolated from systemic IL-6 blockade and general anti-inflammatory principles (Lung Injury, 2005).
How this may change practice
If future well-designed clinical trials demonstrate safety and efficacy, inhaled anti-IL-6 therapies could become a valuable adjunct to existing treatments for severe COVID-19 lung injury, potentially reducing progression to fibrosis and need for lung transplantation. This approach may also extend to other causes of inflammatory lung injury characterized by IL-6 dysregulation.
In the near term, pulmonologists should remain informed about ongoing research and consider enrolling eligible patients in clinical trials investigating inhaled anti-IL-6 agents. Until robust data emerge, routine clinical use outside research settings is not recommended. Multidisciplinary collaboration with critical care, infectious disease, and transplant teams remains essential for managing severe COVID-19-related ARDS.